Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 24Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 3Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Sarcoma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Lung Neoplasms 2Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2mCRPC (Metastatic Castration-resistant Prostate Cancer) 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rectal Neoplasms 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

radium Ra 223 dichloride 2pembrolizumab 2enzalutamide 2abiraterone 2Injections 2Abiraterone Acetate 2niraparib 1efineptakin alfa 1darolutamide 1capivasertib 1cabazitaxel 1apalutamide 1Solutions 1Radium-223 1Prednisone 1Pluvicto 1PSMA-11 1Lutetium-177 1Lutetium 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC) × Injections × Genitourinary × Clear all
NCT06241846 2025-08-27

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03903835 2025-04-09

ProBio

Karolinska Institutet

Phase 3 Recruiting
750 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡